PD-L1 expression on some tumors may result from oncogenic pathways such as PI3 kinase signalling in gliobastomas in association with PTEN deletion, ALK and STAT3 signalling in lymphomas or mutant EGFR activity in lung tumors [10–12]. The gene discussed is CD274; the disease is lymphoma.